Thymosin Alpha-1
Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD exacerbation RCTs, while TESTS 2025 found no clear 28-day sepsis mortality benefit.
Thymosin Alpha-1 scored 6.6 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide → Immune Peptide.
What It Is
Thymosin Alpha-1, also called thymalfasin or TA-1, is a 28-amino-acid thymic peptide used internationally as Zadaxin and in the United States through non-FDA-approved peptide channels. Its core role is immune modulation: TA-1 helps dendritic cells bridge innate and adaptive immunity, nudges T-helper signaling toward antiviral Th1 activity, supports CD4/CD8 recovery in lymphopenic states, and may improve monocyte HLA-DR expression in sepsis-induced immune suppression.
The strongest evidence is not for healthy biohacker immune boosting. It is for people with impaired or stressed immune systems: chronic viral hepatitis patients, older vaccine low responders, severe COVID-19 lymphopenia, sepsis, acute COPD exacerbation, severe acute pancreatitis, and cancer-adjacent immune support. Track 1 surveillance strengthened this picture with Cao et al. 2024 in acute COPD exacerbation, Tian et al. 2025 in severe acute pancreatitis, and Gu et al. 2025 in sepsis RCTs. The most important tempering signal is TESTS 2025, a 1,106-person phase 3 sepsis trial that found no clear 28-day mortality benefit versus placebo while confirming a very clean safety profile.
Mechanistically, the audit-corrected Garaci-linked mechanism citation is not the old mismatched PubMed record. The correct record is Romani et al. 2004, which supports dendritic-cell Toll-like receptor signaling and Th1 immune resistance in a transplant-mouse model. Clinically, hepatitis B evidence should cite Chien et al. 1998 for the 40.6% versus 9.4% complete virologic response, not the previously muddled Chan/Garaci citation chain. The practical bottom line: TA-1 is a high-upside immune-normalization peptide for the right immune-compromised context, but a weaker choice for already healthy young users expecting a noticeable daily effect.
Terminology
- TA-1: Thymosin Alpha-1, also called thymalfasin. A synthetic version is sold internationally as Zadaxin.
- Thymalfasin: Generic drug name for synthetic thymosin alpha-1.
- Zadaxin: Branded thymalfasin product approved in multiple non-US countries but not FDA-approved in the United States.
- Th1 / Th2 polarization: T-helper immune programs. Th1 emphasizes antiviral and anti-tumor cellular immunity; Th2 emphasizes antibody and allergic response patterns.
- TLR9 / TLR2: Toll-like receptors on immune cells that detect danger signals and help activate dendritic-cell immune presentation.
- NF-kB: Nuclear Factor kappa-light-chain-enhancer of activated B cells, a transcription factor downstream of innate immune sensing.
- Dendritic cells: Antigen-presenting immune cells that teach T-cells what to respond to.
- CD4 / CD8: Helper and cytotoxic T-cell markers. A low or distorted CD4/CD8 pattern often reflects immune suppression or immune aging.
- mHLA-DR: Monocyte HLA-DR expression, a marker of immune competence that can drop during sepsis-induced immune suppression.
- NK cells: Natural killer cells that help detect and destroy virus-infected and tumor-like cells.
- IDO: Indoleamine 2,3-dioxygenase, an immune-tolerance pathway that helps keep immune activation from becoming excessive.
- HBeAg: Hepatitis B e antigen, a marker used in chronic hepatitis B activity and treatment response.
- APACHE II: Acute Physiology and Chronic Health Evaluation II, a severity score used in critical-care research.
- 503A / 503B compounding: US pharmacy-compounding frameworks. FDA has flagged thymosin-alpha 1 compounding concerns.
- S0: WADA's non-approved-substance category. The 2026 Prohibited List can create risk for athletes using substances without current governmental approval in their context.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Lyophilized thymosin alpha-1 reconstituted with bacteriostatic water and injected with a 27-30G insulin syringe | 1.6 mg 2x/week to 1.6 mg every 12-24 hours depending on indication and care setting | 1.6 mg 2x/week to 6.4 mg 2-3x/week |
| Intravenous | Reconstituted vial for clinical administration | 1.6 mg every 12 hours for 7 days in ICU trial protocols | Not appropriate outside clinical care |
| Intranasal | Nasal spray formulations sold by some gray-market or compounding channels | No controlled human pharmacokinetic or efficacy range | Empirical; no published dose range |
| Oral lozenge | Sublingual troche or buccal lozenge | No controlled human pharmacokinetic or efficacy range | Empirical |
Protocols
Chronic immune support Clinical
- Dose
- 1.6 mg subcutaneous
- Frequency
- 2x/week
- Duration
- Indefinite or cycled under clinician supervision
Closest to Zadaxin-labeled hepatitis dosing and the default maintenance protocol used by clinicians for immune decline or post-illness recovery.
Acute illness support Mixed
- Dose
- 1.6 mg subcutaneous
- Frequency
- Daily
- Duration
- 7-14 days
Modeled after acute-care intensity, but outpatient use for ordinary viral illness is not directly validated.
Travel prophylaxis Anecdotal
- Dose
- 1.6 mg subcutaneous
- Frequency
- Before and during high-exposure travel
- Duration
- As needed, commonly 5-10 days
Nick's personal use case: break-glass immune support during airports, dense events, or known ill contacts. No RCT evidence for healthy traveler prophylaxis.
Hepatitis B historical protocol Clinical
- Dose
- 1.6 mg subcutaneous
- Frequency
- 2x/week
- Duration
- 26 weeks, with delayed follow-up
[Chien 1998](https://pubmed.ncbi.nlm.nih.gov/9581695/) used 1.6 mg twice weekly and reported higher complete virologic response at 18 months than untreated control.
Sepsis / ICU intensive Clinical
- Dose
- 1.6 mg subcutaneous or intravenous
- Frequency
- Every 12 hours
- Duration
- 7 days
[TESTS 2025](https://pubmed.ncbi.nlm.nih.gov/39814420/) used every-12-hour dosing in adults with sepsis and found no clear 28-day mortality benefit versus placebo.
Community high-dose immune cycle Anecdotal
- Dose
- 3-6.4 mg subcutaneous
- Frequency
- 2-3x/week
- Duration
- 4-8 weeks
Exceeds labeled dosing by 2-4x. Controlled healthy-adult data do not support routine escalation.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.41
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 3.8 | 0.380 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 3.405 |
Upside Rationale
Thymosin Alpha-1 has its best upside when the user matches Thymosin Alpha-1 to the evidence-backed lane instead of treating it as a broad wellness shortcut. The upside is real clinical evidence for immune signaling in sick populations. Thymosin Alpha-1 affects T-cell and dendritic-cell function, and several meta-analyses show signal in COPD exacerbation, pancreatitis, sepsis-adjacent, and antiviral contexts. The most useful anchors are Cao 2024 and Wu 2025, because they explain both the signal and the boundary around that signal. For readers, the so-what is simple: Thymosin Alpha-1 is worth considering when the expected benefit can be observed in a concrete marker, symptom, lab, or performance measure. Thymosin Alpha-1 is weaker when the goal is vague optimization with no baseline and no follow-up.
Efficacy (3.5/5.0). TA-1 has moderate-to-strong efficacy in immune-compromised settings, with the largest modern sepsis RCT tempering earlier mortality claims. Chien et al. 1998 reported complete virologic response in chronic hepatitis B of 40.6% after 26-week TA-1 dosing versus 9.4% control at 18 months. Wu et al. 2013 found severe sepsis mortality of 26.0% versus 35.0%, but the confidence interval crossed no effect. TESTS 2025 then found 23.4% versus 24.1% 28-day mortality, which prevents an efficacy upgrade. New Cao 2024 and Tian 2025 meta-analyses strengthen acute COPD and pancreatitis evidence, but healthy-user prophylaxis remains extrapolated.
Breadth of Benefits (4.0/5.0). TA-1 touches a wide immune surface: dendritic-cell activation, Th1 polarization, CD4/CD8 restoration, NK-cell cytotoxicity, mHLA-DR recovery, IDO-linked tolerance, vaccine-response augmentation, viral-hepatitis immune control, severe respiratory illness, pancreatitis infection risk, sepsis immune suppression, and cancer-adjacent immune surveillance. Liu et al. 2020 supports COVID-19 lymphopenia and exhaustion-marker relevance, while Costantini et al. 2019 reviews cancer-therapy rationale. The breadth is genuine but mostly converges on immune competence. It is not broad in the way creatine, sauna, sleep, or red light touch many everyday health domains.
Evidence Quality (3.0/5.0). Evidence quality remains moderate: there are multiple RCTs, meta-analyses, and decades of international use, but authority gaps and trial geography constrain confidence. Gu et al. 2025 pooled sepsis RCTs favorably, yet the TESTS 2025 trial was neutral on mortality. Chan et al. 2001 and Wu et al. 2015 support historical hepatitis B efficacy, but current AASLD/IDSA 2025 guidance does not position TA-1 as preferred routine therapy. Cochrane has a withdrawn older review and a newer protocol, not a completed positive review. This justifies holding evidence at 3.0.
Speed of Onset (3.5/5.0). TA-1 can change immune markers within days in acute-care contexts. In Wu et al. 2013, mHLA-DR improved by day 3 and day 7 versus control, matching the travel-prophylaxis logic of loading before high exposure. Adaptive markers such as CD4 cells and CD4/CD8 ratio generally need 1-2 weeks, while hepatitis B virologic endpoints can emerge after treatment cessation. That makes TA-1 faster than most immune-support supplements for measurable immune markers, but slower and less subjectively obvious than sleep, stimulants, or acute symptom relievers.
Durability (3.8/5.0). TA-1's durability is a distinguishing advantage because immune education can outlive the dosing window. Chien et al. 1998 found response separation at 18 months even though end-of-treatment response rates were similar, which is consistent with delayed immune control rather than direct antiviral pressure. Vaccine-adjuvant work summarized by Ershler et al. 2007 also fits the model: short exposure can alter downstream immune response. Healthy-user durability is less proven, but in the right responder, TA-1 behaves more like an immune-training intervention than a continuous receptor-occupying drug.
Bioindividuality Upside (3.0/5.0). TA-1 is highly responder-dependent. Best responders are people with immune compromise: older adults, lymphopenia, low CD4 cells, poor CD4/CD8 ratio, low mHLA-DR, chronic viral carriers, severe inflammatory illness, post-chemotherapy suppression, or high pathogen exposure. The FDA orphan-designation record and international clinical history reflect serious immune-linked indications, not casual optimization. Healthy young adults with robust thymic output may feel nothing and may show minimal biomarkers. That ceiling is why the score rewards targeted use while capping general wellness enthusiasm.
Downside contribution: 1.79 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.2 | 0.360 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.365 | |||
| Harm subtotal × 1.4 | 1.491 | |||
| Opportunity subtotal × 1.0 | 0.300 | |||
| Combined downside | 1.791 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.451 |
Downside Rationale
Thymosin Alpha-1's main downside is not one isolated risk; it is the mismatch between marketing certainty and the actual evidence base. The downside is context mismatch. Most evidence comes from acute or medically supervised settings, while wellness use often extrapolates to healthy adults. Injectable sourcing, immune-disease context, cancer context, and medication interactions need clinician oversight. Tian 2025 is the anchor that keeps the safety discussion honest, while Cao 2024 helps define where the benefits are strongest. The practical move is to treat Thymosin Alpha-1 as a targeted experiment, not a default habit. That means checking contraindications, product quality, dose, medication conflicts, and the opportunity cost of skipping better-supported basics before assigning Thymosin Alpha-1 a permanent role.
Safety risk (1.2/5.0). Intrinsic TA-1 safety is very clean in controlled trials, but the real-world risk is context and sourcing. TESTS 2025 reported overall adverse events of 66.4% with TA-1 versus 67.6% with placebo, with no unexpected serious drug-related events. Gravenstein 1989 reported no toxicity in an elderly vaccine-adjuvant trial. The serious cautions are active autoimmune disease, transplant status, immunosuppressive therapy, pregnancy or lactation, active cancer protocols without oncologist oversight, and athletes subject to S0 non-approved-substance analysis. FDA compounding materials add a separate product-quality risk around impurities and characterization.
Side effect profile (1.5/5.0). Side effects are usually mild and injection-related: sting, redness, transient local irritation, and occasional flu-like malaise during the first day or two. The best large safety dataset, TESTS 2025, shows placebo-like overall adverse-event rates, while older hepatitis and vaccine studies did not surface a consistent systemic side-effect pattern. TA-1 has no known tolerance, withdrawal, stimulant crash, gut-motility disruption, or endocrine suppression signal. The main reason side effects score above the floor is that sterile injection, compounded-product variability, and immune activation make it less trivial than an oral nutrient.
Financial cost (2.5/5.0). TA-1 is meaningfully more expensive than standard immune-support supplements. US compounded access commonly costs about $100-400 per month at 1.6 mg twice weekly, while branded Zadaxin internationally can run materially higher. Research-use products may look cheaper but shift risk to purity, sterility, and identity testing. For travel-only use, cost is tolerable; for chronic use, it becomes a real stack expense.
Time / effort burden (2.0/5.0). Twice-weekly subcutaneous injection is not hard for experienced peptide users but is a real barrier for people accustomed to capsules. Reconstitution, sterile handling, syringe prep, site rotation, and refrigeration add friction. Acute protocols can require daily or every-12-hour dosing in clinical settings. Intranasal and oral shortcuts lack controlled support, so the evidence-backed route keeps effort above oral-supplement level.
Opportunity cost (1.5/5.0). TA-1 stacks well with immune fundamentals, so the main opportunity cost is using it to avoid basics. Sleep, adequate protein, vitamin D sufficiency, exercise, vaccination when appropriate, infection control, and clinician-directed antiviral or antibiotic therapy outrank TA-1 for most users. For chronic hepatitis B, current NICE guidance and AASLD/IDSA surfaces emphasize standard antiviral care, not thymalfasin. As an adjunct during high-risk exposure or immune recovery, opportunity cost is low; as a substitute for first-line medicine, it rises quickly.
Dependency / withdrawal (1.2/5.0). TA-1 has no known physiological dependency, withdrawal syndrome, or receptor-downregulation pattern. Stopping simply removes the exogenous signal and lets immune tone drift back toward baseline over weeks to months. The delayed hepatitis response pattern and vaccine-adjuvant framing support intermittent or cyclical use rather than continuous dependence. Users can start, stop, or reserve TA-1 for travel or recovery windows without a taper.
Reversibility (1.2/5.0). TA-1 is highly reversible because the molecule clears quickly and does not permanently alter tissue structure, endocrine axes, or organ anatomy. Any immune training effect fades rather than rebounds below baseline. The exceptions are not molecule permanence but medical context: a transplant recipient, autoimmune patient, pregnant user, or athlete using non-approved product has consequences that cannot be reduced to pharmacokinetic clearance. For ordinary supervised use, reversibility is one of TA-1's strongest downside features.
Verdict
Thymosin Alpha-1 is a 6.6/10 fit for people discussing immune modulation with a clinician, especially in hospital-adjacent or immune-compromised contexts, not a casual immune booster for healthy people. The cleanest evidence anchors are Cao 2024, which pooled 39 acute COPD exacerbation RCTs, and Wu 2025, which found no clear 28-day mortality benefit in a large sepsis trial. Tian 2025 adds useful context: reported infection and immune-marker benefits in severe acute pancreatitis trials. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, Thymosin Alpha-1 belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.
✅ Best for: Adults over 40 with signs of immune aging or poor vaccine response; frequent travelers exposed to airports, dense events, or ill contacts; people recovering from illness, surgery, or chemotherapy-associated immune suppression; patients with documented low CD4, poor CD4/CD8 ratio, low mHLA-DR, or lymphopenia; and chronic viral hepatitis or cancer patients only as adjunctive care under the relevant specialist. TA-1 is strongest when there is an immune deficit to normalize, not when a healthy young user wants a dramatic daily effect.
❌ Avoid if: You have active autoimmune disease, recent autoimmune flare, transplant history, immunosuppressive therapy, pregnancy, lactation, or no way to verify sterile sourcing and peptide identity. Avoid replacing first-line hepatitis B, sepsis, COPD, pancreatitis, COVID-19, or cancer care with TA-1. Competitive athletes should avoid unsupervised use unless a qualified anti-doping expert clears the jurisdiction-specific S0 risk. Healthy under-30 users with robust immune function should usually spend the money on sleep, exercise, nutrition, vaccines, and travel hygiene first.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Immune Function: 9.0/10
Score: 9.0/10Thymosin Alpha-1 immune function earns 9.0/10 because Cao 2024 anchors the most relevant signal. Thymosin Alpha-1 fits immune function when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Geriatric / Aging Population: 7.5/10
Score: 7.5/10Thymosin Alpha-1 geriatric earns 7.5/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits geriatric when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Respiratory: 6.5/10
Score: 6.5/10Thymosin Alpha-1 respiratory earns 6.5/10 because Cao 2024 anchors the most relevant signal. Thymosin Alpha-1 fits respiratory when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Liver / Detoxification: 7.0/10
Score: 7.0/10Thymosin Alpha-1 liver detox earns 7.0/10 because Tian 2025 anchors the most relevant signal. Thymosin Alpha-1 fits liver detox when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Anti-Inflammatory: 7.0/10
Score: 7.0/10Thymosin Alpha-1 anti inflammatory earns 7.0/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits anti inflammatory when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Healthspan: 6.5/10
Score: 6.5/10Thymosin Alpha-1 healthspan earns 6.5/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits healthspan when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Longevity / Lifespan: 6.0/10
Score: 6.0/10Thymosin Alpha-1 longevity earns 6.0/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits longevity when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Neuroprotection: 6.0/10
Score: 6.0/10Thymosin Alpha-1 neuroprotection earns 6.0/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits neuroprotection when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
Wound Healing: 5.5/10
Score: 5.5/10Thymosin Alpha-1 wound healing earns 5.5/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits wound healing when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is in sick or medically supervised populations rather than healthy optimization. In practice, Thymosin Alpha-1 is most defensible when someone tracks infection frequency, immune labs, respiratory symptoms, medication changes, liver markers, and clinician-defined endpoints instead of relying on a vague before-and-after feeling. Thymosin Alpha-1 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a clinician-led immune experiment with clear stop rules.
| Use Case | Score | Summary |
|---|---|---|
| ○ Cardiovascular | 4.0 | Cardiovascular relevance is mostly secondary to sepsis and critical illness outcomes. Wu 2013 tracked severe sepsis outcomes, but no primary cardiovascular prevention or treatment indication is established. |
| ○ Gut Health / Microbiome | 4.0 | Gut-barrier benefit is indirect through immune regulation. Tian 2025 severe acute pancreatitis data are abdominal and infection-adjacent, but not a general gut-health RCT. |
| ○ Recovery / Repair | 4.0 | Recovery-repair relevance comes from immune-mediated infection control and post-illness immune restoration. No athletic recovery trial supports thymosin alpha-1 as a muscle or connective-tissue recovery intervention. |
| ○ Hormonal / Endocrine | 3.5 | Thymosin alpha-1 is a thymic peptide hormone but not a direct endocrine modulator. Effects on classic hormones such as thyroid, testosterone, cortisol, or insulin are not established in controlled human trials. |
| ○ Skin / Beauty | 3.5 | Skin benefit is indirect through wound and immune regulation. There is no acne, collagen, photoaging, or hair-follicle human evidence comparable to dermatologic photobiomodulation or retinoid trials. |
| ○ Stress / Resilience | 3.5 | Stress resilience is mechanistic and contextual: immune suppression during illness or travel may improve, but there are no direct stress, cortisol, resilience, or burnout trials in healthy adults. |
| ○ Neuroplasticity | 3.5 | Animal neurogenesis pathways exist, but human neuroplasticity endpoints are not established. Keep this exploratory and do not treat thymosin alpha-1 as a cognitive-enhancement peptide. |
| ○ Antioxidant / Oxidative Stress | 3.5 | Oxidative-stress changes appear secondary to inflammation and immune regulation, not direct antioxidant action. No robust human antioxidant-marker program supports thymosin alpha-1 as a primary antioxidant. |
| ○ Injury Recovery | 3.5 | Injury recovery is indirect through infection defense and immune repair. There are no direct human trials for tendon, ligament, fracture, concussion, or sports-injury recovery. |
| ○ Metabolic Health | 3.0 | No direct metabolic-health evidence. A TESTS 2025 subgroup signal by diabetes was exploratory and does not establish glucose, insulin, or weight benefits. |
| ○ Lymphatic / Drainage | 3.0 | Thymic education and T-cell trafficking touch lymphoid biology, but no direct lymphatic-flow, edema, or lymphatic-system trial supports a higher score. |
| ○ Cognition / Focus | 3.0 | No human cognition-focus trial exists. Any cognitive rationale depends on immune-brain signaling and illness recovery, not direct nootropic evidence. |
| ○ Mood / Emotional Regulation | 3.0 | Immune-mood links are real in general medicine, but thymosin alpha-1 has no direct depression, anxiety, or mood RCT. Use this as exploratory only. |
| ○ Nerve Regeneration | 3.0 | Animal neurogenesis data do not equal nerve-regeneration evidence. No peripheral neuropathy, nerve crush, diabetic neuropathy, or radiculopathy human RCT supports clinical use. |
| ○ Cellular Senescence | 3.0 | Immune surveillance of senescent cells is a plausible pathway, but thymosin alpha-1 has no human senescence-marker trial. This remains a low-confidence healthspan extension angle. |
| ○ Energy / Fatigue | 3.0 | Some users report better energy during illness, but no objective fatigue or energy endpoint is established. Effects likely reflect recovery from immune suppression rather than stimulant-like energy. |
| ○ Pediatric Use | 3.0 | Some pediatric immune-deficiency contexts exist historically, but thymosin alpha-1 is not a default pediatric intervention. Pediatric use requires specialist supervision. |
Frequently Asked Questions
What is Thymosin Alpha-1 and how does it work?
Thymosin Alpha-1 is a 28-amino-acid thymic peptide that regulates innate-to-adaptive immune signaling. Romani 2004 showed dendritic-cell activation through Toll-like receptor signaling and Th1 resistance in a preclinical model. In humans, the clinical pattern is immune restoration: CD4/CD8 normalization, improved antigen presentation, NK-cell support, and less immune exhaustion in compromised disease states.
What is the best dose and schedule for Thymosin Alpha-1?
The most defensible wellness-adjacent schedule is 1.6 mg subcutaneous twice weekly, matching historical Zadaxin-style chronic protocols. Acute-care trials can use more intensive dosing: TESTS 2025 used 1.6 mg every 12 hours for seven days in sepsis. Community 3-6.4 mg cycles exceed the evidence base. Oral and intranasal forms should not be treated as equivalent because controlled absorption data are missing.
Does Thymosin Alpha-1 actually work for viral infections and hepatitis?
Yes for some historical viral indications, but it is not modern first-line hepatitis care. Chien 1998 reported chronic hepatitis B complete virologic response of 40.6% with 26-week treatment versus 9.4% control at 18 months, while Liu 2020 reported severe COVID-19 lymphopenia and T-cell exhaustion reversal signals. Current major HBV guidance still prioritizes nucleoside or nucleotide antivirals.
Does Thymosin Alpha-1 have evidence in sepsis, COPD, or pancreatitis?
Yes, but the acute-care signal is mixed and context-specific. Cao 2024 pooled 39 acute COPD exacerbation RCTs and reported broad lung-function and immune-marker improvements. Tian 2025 pooled five severe pancreatitis RCTs and found CD4/CD8 and infection benefits. In sepsis, TESTS 2025 found no clear 28-day mortality reduction, tempering earlier optimism.
Can I use Thymosin Alpha-1 for travel or general immune support?
Travel use is reasonable only as an extrapolated, high-exposure protocol, not as a proven healthy-adult prophylactic. The best data come from immune-compromised or acutely ill populations, not optimized 25-year-olds. Adults over 40, frequent travelers, healthcare workers, and people recovering from illness fit the mechanism better than healthy young users. Expect fewer infections or smoother recovery if it helps, not a dramatic subjective effect.
Is Thymosin Alpha-1 safe and what side effects should I expect?
Controlled-trial safety is unusually clean, but product quality and immune context matter. TESTS 2025 reported overall adverse events of 66.4% with thymosin alpha-1 versus 67.6% with placebo and no unexpected serious drug-related events. Common user-level issues are injection-site redness, sting, and transient flu-like symptoms. Avoid active autoimmune disease, transplant status, immunosuppressive therapy, pregnancy, and unverified peptide vendors.
Zadaxin vs compounded Thymosin Alpha-1: which should I source?
Zadaxin is the branded thymalfasin product used internationally; US users do not have an FDA-approved thymalfasin drug product. FDA materials flag thymosin-alpha-1 compounding concerns around immunogenicity, peptide impurities, and active-ingredient characterization. Research-use vials without third-party purity testing are the major real-world risk. If used, it should be clinician-supervised, sterile, tested, and legally sourced.
Can I stack Thymosin Alpha-1 with BPC-157 or other peptides?
Thymosin Alpha-1 has few known direct drug interactions, but stacking increases sourcing, cost, and attribution problems. It pairs conceptually with immune fundamentals, vitamin D sufficiency, sleep, aerobic fitness, and recovery peptides, yet controlled stack trials do not exist. The main caution is not pharmacology alone: autoimmune disease, transplant medicine, immunosuppressants, anti-doping rules, and poor-quality compounded or research products dominate the risk assessment.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large Western-funded RCT confirms a sepsis mortality benefit in immune-suppressed patients | Evidence 3.0 to 3.8 | 7.2 / 10 💪 Strong recommend |
| FDA approves thymalfasin for sepsis, chronic hepatitis B, or another immune-restoration indication | Evidence 3.0 to 4.0; Bioindividuality 3.0 to 3.2 | 7.4 / 10 💪 Strong recommend |
| Large healthy-adult travel prophylaxis RCT shows no reduction in infections | Efficacy 3.5 to 3.0; Bioindividuality 3.0 to 2.5 | 6.6 / 10 💪 Strong recommend |
| Autoimmune flare signals emerge in long-term post-market surveillance | Safety 1.2 to 2.5; Side effects 1.5 to 2.5 | 6.2 / 10 👍 Worth trying |
| Oral bioavailable formulation with human pharmacokinetic confirmation launches | Effort 2.0 to 1.2 | 7.0 / 10 💪 Strong recommend |
| Completed Cochrane review confirms hepatitis and acute-care meta-analysis findings | Evidence 3.0 to 3.8 | 7.2 / 10 💪 Strong recommend |
| User sources from unverified research peptide vendor with poor purity or sterility | Effective efficacy 3.5 to 2.0; Safety 1.2 to 2.3 | 5.9 / 10 👍 Worth trying |
Key Evidence Sources
- Cao et al. 2024 - Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: systematic review and meta-analysis. 39 RCTs; 3,329 patients; adjunctive TA-1 improved lung function, blood gases, hospital stay, and T-cell markers with heterogeneity and risk-of-bias caveats.
- Tian et al. 2025 - Thymosin alpha 1 alleviates inflammation and prevents infection in severe acute pancreatitis: systematic review and meta-analysis. 5 RCTs; 706 patients; increased CD4 cells and CD4/CD8 ratio, reduced extrapancreatic infections, and lowered APACHE II score.
- Gu et al. 2025 - Efficacy of thymosin alpha1 for sepsis: systematic review and meta-analysis of RCTs. 11 RCTs; 1,927 patients; pooled 28-day mortality favored TA-1 but evidence remains heterogeneous and guideline uptake lags.
- Wu et al. 2025 - TESTS phase 3 sepsis trial, BMJ. 1,106 randomized adults with sepsis; no clear 28-day mortality benefit; adverse-event rates similar to placebo.
- BMJ 2025 - TESTS trial correction and updated data. Correction notice for the BMJ TESTS trial data update; retained to document the current trial record.
- Wu et al. 2013 - ETASS severe sepsis multicenter randomized controlled trial. 361 severe sepsis patients; 28-day mortality 26.0% vs 35.0%, RR 0.74 with confidence interval crossing 1.0; improved mHLA-DR.
- Liu et al. 2020 - Severe COVID-19 retrospective cohort. Severe COVID-19 cohort; TA-1 associated with lymphopenia recovery and T-cell exhaustion-marker reversal; author/year corrected from v0.x mismatch.
- Romani et al. 2004 - Thymosin alpha 1 activates dendritic cells through toll-like receptor signaling. Corrected Garaci-linked 2004 mechanism record; supports dendritic-cell TLR/MyD88 signaling and Th1 antifungal immunity in transplant-mouse models.
- Garaci et al. 2024 - Phenotypic drug discovery: a case for thymosin alpha-1. Narrative review and modern mechanism framing; not treated as a qualifying efficacy upgrade.
- Costantini et al. 2019 - A reappraisal of Thymosin Alpha1 in cancer therapy. Cancer-immunology review covering immune surveillance, checkpoint-adjacent rationale, and therapeutic context.
- Chien et al. 1998 - Efficacy of thymosin alpha1 in chronic hepatitis B: randomized controlled trial. 98 patients; 26-week 1.6 mg twice-weekly group had 40.6% complete virologic response vs 9.4% control at 18 months.
- Chan et al. 2001 - The efficacy of thymosin in chronic hepatitis B virus infection: meta-analysis. Historical HBV meta-analysis; supports delayed response pattern but predates modern first-line antiviral guidance.
- Wu et al. 2015 - Thymosin alpha-1 treatment in chronic hepatitis B. Expert review of CHB trials; notes need for better-designed studies and combination therapy exploration.
- Gravenstein et al. 1989 - Influenza antibody response in elderly men. Double-blind placebo-controlled trial in older men testing TA-1 as an influenza vaccine adjuvant.
- Ershler et al. 2007 - Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly. Trial-summary review of TA-1 vaccine-adjuvant rationale in elderly low responders.
- Panatto et al. 2011 - Utility of thymosin alpha-1 as a co-adjuvant in influenza vaccines. Review of influenza vaccine co-adjuvant use in elderly and immunocompromised populations.
- FDA - Certain bulk drug substances for use in compounding that may present significant safety risks. FDA lists thymosin-alpha 1 compounding concerns: immunogenicity, peptide impurities, active-ingredient characterization, and inadequate safety information.
- FDA - Orphan drug designation for thymalfasin in hepatocellular carcinoma. FDA orphan listing states thymalfasin is designated but not FDA-approved for the orphan indication.
- Cochrane - Thymosin alpha1 for chronic hepatitis B withdrawn review. Withdrawn Cochrane review; authority gap rather than endorsement.
- Cochrane - Thymosin-alpha1 for people with chronic hepatitis B protocol. Protocol for a chronic hepatitis B review; no completed positive Cochrane review available.
- AASLD/IDSA 2025 - Practice Guideline Update on Treatment of Chronic Hepatitis B. Current major-society guidance surface does not position thymosin alpha-1 as routine or preferred HBV therapy.
- NICE - Hepatitis B chronic diagnosis and management. NICE chronic hepatitis B guidance surface; thymosin alpha-1 not identified as a recommended therapy.
- WADA - 2026 Prohibited List. Thymosin alpha-1 not found as a named prohibited substance in searched WADA surface; non-approved-substance S0 risk remains jurisdiction-sensitive.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Cao 2024, Tian 2025, Gu 2025, Wu 2025, Wu 2013, Liu 2020, Chien 1998, Romani 2004, FDA 2025, AASLD/IDSA 2025
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Gravenstein 1989, Chien 1998, Chan 2001, Ershler 2007
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Thymosin Alpha-1
The three lenses converge on one narrow idea: thymic signaling can influence immune competence, especially when immune function is impaired. Modern trials identify disease contexts, biomarkers, and safety boundaries; historical development explains why hepatitis, vaccine response, sepsis, and cancer became the core indications; traditional organotherapy supplies only a loose precursor. The honest synthesis is targeted immune restoration, not generic immune enhancement. Thymosin alpha-1 deserves a strong but bounded score because benefit depends heavily on immune substrate, route quality, and medical context.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- WBC Baseline (pre-protocol)
- Absolute Lymphocytes During | Expected Watch
- Absolute Neutrophils During | Expected Stable
- hs-CRP During | Expected Down
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Infection Frequency Scale 1-5 | During | Expected Down
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
- Immune Flare Symptoms Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- Autoimmune flare symptoms
Other interventions for Immune Function
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.405 − 0.451 = 1.954
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.954 / 5) × 5 = 7.0 / 10
